AtriCure Reports Strong Q2 Earnings with Revenue Growth and Return to Profitability
AtriCure reported strong second-quarter results in 2026, posting a revenue increase of 12.8% year-over-year to $153.6 million and returning to GAAP profitability for the first time since Q4 2023. Adjusted EBITDA surged by 78%, reaching $27.3 million, while net income improved significantly from a loss of $6.2 million in the prior year period to a profit of $9 million. The company's growth was driven primarily by its pain management segment, which saw worldwide revenue rise 27% due to strong adoption of CryoSphere MAX and early traction with CryoXT. Open ablation also contributed positively, while minimally invasive ablation continued to face challenges. AtriCure raised its full-year guidance for both revenue ($602–$610 million) and adjusted EBITDA ($85–$89 million), reflecting confidence in sustained performance. Management highlighted ongoing clinical trials such as BoxX-NoAF and LeAAPS, which could support future label expansions. The company remains optimistic about long-term growth prospects driven by product adoption and evolving surgical guidelines.
Tickers: $ATRC
Topics: ebitda financial_results medical_devices revenue_growth